Loading
Heart Failure / Titration during the randomization phase / Implant of investigational device system · Interventional Study
ClinicalTrials.gov · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registry record for the NECTAR-HF feasibility trial, a device-based intervention study of right vagal nerve stimulation in heart failure. The record documents the trial design and enrollment (118 participants) but reports no outcomes. Results are not yet posted in this registry entry.
Interventional, Randomized, Crossover, Double masking, Treatment purpose. Heart Failure, Congestive Heart Failure; age from 18 Years. Intervention: Therapy. Compared with: Control — Sham Comparator. n = 118. 21 sites across 8 countries.
This is a registry record for the NECTAR-HF feasibility trial, a device-based intervention study of right vagal nerve stimulation in heart failure. The record documents the trial design and enrollment (118 participants) but reports no outcomes. Results are not yet posted in this registry entry.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is a registry record for an active feasibility trial with no reported results; the design and enrollment are documented but outcomes remain unreported.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT01385176). This is a study registration, not published results. Lead sponsor: Boston Scientific Corporation. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 118 participants (ACTUAL). Conditions: Heart Failure, Congestive Heart Failure. Interventions: DEVICE: Implant of investigational device system; PROCEDURE: Titration during the randomization phase; PROCEDURE: Titration after the randomization phase; DIAGNOSTIC_TEST: Blood Draw. Primary outcome measures: Change in Left Ventricular End-systolic Dimension (LVESD) , LVESD at Baseline and at 6-months post Baseline; Percentage of Surviving Participants , 18-months. Brief summary: The NECTAR-HF feasibility trial is designed to evaluate the application of right vagal nerve stimulation in heart failure patients with a New York Heart Association Class III, an ejection fraction equal to or less than 35 %, and a narrow QRS duration equal to or less than 130 ms.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.